Discover the Future of Alzheimer’s disease treatment

DRG Disease Landscape & Forecast

Key trends in Alzheimer’s disease treatment:

Beta-Amyloud MAbs are reshaping treatment pathways

  • Leqembi (Eisai/Biogen) and Kisunla (Eli Lilly) are now competing in the early AD space.
  • The U.S. and Japan approvals signal a turning point, but European market access remains a challenge.

Next-generation DMTs are in development

  • Eli Lilly’s remternetug and Novo Nordisk’s semaglutide could offer new treatment options in the coming years.
  • Expect additional filings for maintenance IV/SC dosing and subcutaneous delivery of existing agents.

Neuropsychiatric symptom management is gaining momentum

  • Lundbeck/Otsuka’s Rexulti is the first FDA-approved therapy for AD-related agitation.
  • Axsome’s Auvelity and Bristol Myers Squibb’s Cobenfy are in late-phase development for psychosis and agitation in AD.
Contact sales for pricing details north_east

Request more information

The Alzheimer’s Disease – Disease Landscape & Forecast (G7) report delivers comprehensive insights into disease-modifying therapies (DMTs), symptomatic treatments, and evolving market dynamics. With 10-year sales forecasts, expert analysis, and real time pipeline intelligence from Cortellis, this report equips you with the strategic foresight needed to excel in the competitive Alzheimer’s Disease space.

Book a demoperson_pin

Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.

Key questions answered:

  • How will competition between anti-amyloid (anti-Aβ) MAbs evolve in the AD market through 2033?

  • What do key opinion leaders (KOLs) think of recently approve therapies and upcoming treatments?

  • What is the likely uptake for Axsome’s Auvelity and BMS’s Cobenfy for AD agitation and psychosis?

  • What are the key market drivers and constraints, and how will they evolve with premium-priced agents?

 

View the sample deckfile_download

Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.

10-year market forecast (2023–2033)

Annualized drug-level sales and patient share projections across the U.S., EU5, and Japan.

Global Epidemiology & Market Segmentation

Total, diagnosed, and drug-treated cases, segmented by mild cognitive impairment, mild, moderate, and severe AD.

Pipeline Intelligence Powered by Cortellis

Real-time updates on current and emerging therapies, including beta-amyloid MAbs, neuropsychiatric drugs, and next-gen DMTs.

Primary Research with 20 thought-leading Neurologists

Expert perspectives on treatment adoptions, unmet needs, and future opportunities.

Stay ahead with Alzheimer’s disease Market Intelligence

Ensure your strategy is informed by the latest trends, forecasts, and competitive insights in Alzheimer’s disease treatment.

Request pricing information 3p

What is Disease Landscape & Forecast?

Disease Landscape & Forecast is a premier market intelligence platform, offering:

  • Comprehensive market data including world-class epidemiology, current and emerging therapy insights, and robust drug forecasts

  • Dynamic updates ensuring continuous enhancements to reflect indication-specific developments throughout the year

  • Real-time pipeline intelligence coming directly from Cortellis, with daily updates and interactive figures for in-depth analysis

 

Request more informationnorth_east

Already a Disease Landscape & Forecast client?

Log in login

Expert Insights on Alzheimer’s disease

Built on expert knowledge and rigorous research

  • 20 expert interviews with leading neurologists across the G7 markets
  • Comprehensive epidemiological modeling for Alzheimer’s disease subpopulations.
  • Real-time pipeline intelligence tracking the most promising therapies.

 

Access the brochurefile_download

Request more information